What is Automata?
Automata operates at the intersection of robotics, software engineering, and life sciences. The company provides an integrated platform that combines modular laboratory benches with sophisticated orchestration software, enabling research institutions and clinical labs to scale their operations efficiently. By automating repetitive tasks, Automata helps organizations generate high-quality, reproducible data, which is vital for discovery and diagnostic processes. Its market position is defined by its ability to bridge the gap between traditional manual laboratory processes and the future of fully autonomous, data-driven research facilities.
How much funding has Automata raised?
Automata has raised a total of $142.4M across 4 funding rounds:
Series A
$7.4M
Series B
$50M
Other Financing Round
$40M
Series C
$45M
Series A (2019): $7.4M, investors not publicly disclosed
Series B (2022): $50M led by ABB Technology Ventures, Latitude Ventures, Isomer Capital, Hummingbird, and Octopus Ventures
Other Financing Round (2023): $40M supported by Hummingbird, Octopus Ventures, Aldea Ventures, Possible Ventures, and Isomer Capital
Series C (2026): $45M featuring Octopus Ventures, Entrepreneur First, Tru Arrow Partners, and Danaher
Key Investors in Automata
Octopus Ventures
Octopus Ventures is a founder-focused venture capital firm backing mission-driven companies across software, climate, health, and financial technology, offering long-term capital and strategic guidance.
Danaher
Danaher Corporation is a global leader in life sciences and diagnostics, providing integrated solutions and specialized equipment that enable complex drug development and laboratory analysis.
Entrepreneur First
Entrepreneur First is an international talent investor that supports high-potential individuals in building and scaling transformative technology companies from the ground up.
What's next for Automata?
With this major strategic investment, Automata is expected to focus on expanding its footprint within the global biotechnology and clinical diagnostics markets. The company will likely prioritize the enhancement of its orchestration software capabilities and the scaling of its modular hardware production to meet the needs of enterprise-level clients. As the life sciences industry continues to prioritize speed and accuracy in drug development, Automata's platform is well-positioned to become a standard component of the modern laboratory ecosystem. Future growth will likely involve deeper integration with existing laboratory information management systems and the expansion of its service offerings to support more complex, multi-disciplinary research workflows.
See full Automata company page
